Pro Medicus Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pro Medicus Ltd (PME)
Pro Medicus Ltd stock price live, this page displays ASX PME stock exchange data. View the PME premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pro Medicus Ltd real time stock price chart below.
What Is the Pro Medicus Ltd Stock Price Today?
The Pro Medicus Ltd stock price today is 181.48.
What Is the Stock Symbol for Pro Medicus Ltd?
The stock symbol for Pro Medicus Ltd is "PME."
What Stock Exchange Does Pro Medicus Ltd Trade On?
Pro Medicus Ltd is listed and trades on the Sydney stock exchange.
Is Pro Medicus Ltd a Good Stock to Buy?
Determining whether Pro Medicus Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PME quote. (ISIN: AU000000PME8)
What Is the Pro Medicus Ltd Stock Price Today?
The Pro Medicus Ltd stock price today is 181.48.
What Is the Stock Symbol for Pro Medicus Ltd?
The stock symbol for Pro Medicus Ltd is "PME."
What Stock Exchange Does Pro Medicus Ltd Trade On?
Pro Medicus Ltd is listed and trades on the Sydney stock exchange.
Is Pro Medicus Ltd a Good Stock to Buy?
Determining whether Pro Medicus Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PME quote. (ISIN: AU000000PME8)
181.48
+2.24(+1.25%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
180.45
187.16
52 wk Range
107.75
321.57
PME is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
180.45187.16
52 wk Range
107.75321.57
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.38%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.38%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
PME Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
202.47
Upside
+11.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a low P/E ratio relative to near-term earnings growth
Pro Medicus Ltd receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Pro Medicus Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Pro Medicus Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Pro Medicus Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Pro Medicus Ltd receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
9 Buy
5 Hold
1 Sell
Ratings:
15 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 202.47
(+11.57% Upside)
Pro Medicus Ltd Earnings Call Summary for H2/2026
- Pro Medicus reported record FY 2026 results with revenue of AUD 261.7M and EBIT of AUD 196M, achieving margins near 75% and a 12.4% stock surge.
- Recurring contract coverage reached AUD 1.3B over five years; company secured 10 new contracts including UCHealth and Beth Israel with 100% renewal rate.
- Management guided FY 2027 constant-currency revenue and EBIT growth above 30%, supported by new implementations and product launches in reporting and pathology.
- North America now represents over 90% of revenue; company serves 11 of top 20 U.S. News Best Hospitals with margins 3x higher than nearest competitor.
- Dividend increased 25.5% to AUD 0.69 per share; cash reserves grew to AUD 250M despite AUD 11.8M currency headwinds impacting reported results.
Last Updated: 2026/08/18, 04:22
Read Full TranscriptEarnings
Latest Release
Aug 17, 2026
EPS / Forecast
0,90 / 0,69
Revenue / Forecast
136,91M / 132,17M
Compare PME to Peers and Sector
Metrics to compare | PME | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPMEPeersSector | |
|---|---|---|---|---|
P/E Ratio | 73.2x | 19.1x | −0.4x | |
PEG Ratio | 0.55 | 0.19 | 0.00 | |
Price/Book | 43.1x | 2.4x | 2.6x | |
Price / LTM Sales | 74.2x | 2.2x | 3.1x | |
Upside (Analyst Target) | 22.3% | 27.3% | 47.0% | |
Fair Value Upside | Unlock | 11.8% | 5.6% | Unlock |
Pro Medicus Limited, a healthcare informatics company, provides medical imaging software and services to hospitals, imaging centers, and health care groups in Australia, Europe, and North America. The company offers Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, typing, HL7 integration, financial reporting, picture archive and communication system (PACS) integration, digital dictation, and voice recognition integration; and Visage RIS/PACS, a solution for imaging needs of organizations. It also provides Visage 7 Enterprise Imaging Platform, a healthcare imaging software for radiologists, physicians, and clinicians for access and visualization capability comprising rapidly viewing 2-D, 3-D, and 4-D medical images, as well as PACS, digital imaging software, training, installation, and professional services and support products; and Visage Ease, a native mobile application for access to medical imaging results stored on a Visage 7 server from iOS devices, including iPad, iPhone, and iTouch. In addition, the company offers Visage Ease Pro for interpreting diagnostic imaging studies; and Promedicus.net, an e-health offering. Pro Medicus Limited was incorporated in 1983 and is headquartered in Richmond, Australia.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Pro Medicus Ltd (PME) Stock Price Today?
The Pro Medicus Ltd stock price today is 181,48 AUD.
What Stock Exchange Does Pro Medicus Ltd Trade On?
Pro Medicus Ltd is listed and trades on the Sydney Stock Exchange.
What Is the Stock Symbol for Pro Medicus Ltd?
The stock symbol for Pro Medicus Ltd is "PME."
Does Pro Medicus Ltd Pay Dividends? What’s The Current Dividend Yield?
The Pro Medicus Ltd dividend yield is 0.38%.
What Is the Pro Medicus Ltd Market Cap?
As of today, Pro Medicus Ltd market cap is 18,96B AUD.
What Is Pro Medicus Ltd's Earnings Per Share (TTM)?
The Pro Medicus Ltd EPS (TTM) is 2,54.
When Is the Next Pro Medicus Ltd Earnings Date?
Pro Medicus Ltd will release its next earnings report on Aug 18, 2026.
From a Technical Analysis Perspective, Is PME a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Pro Medicus Ltd Stock Split?
Pro Medicus Ltd has split 0 times.
How Many Employees Does Pro Medicus Ltd Have?
Pro Medicus Ltd has 153 employees.
What is the current trading status of Pro Medicus Ltd (PME)?
As of Aug 28, 2026, Pro Medicus Ltd (PME) is trading at a price of 181,48 AUD, with a previous close of 179,24 AUD. The stock has fluctuated within a day range of 180,45 AUD to 187,16 AUD, while its 52-week range spans from 107,75 AUD to 321,57 AUD.
What Is Pro Medicus Ltd (PME) Price Target According to Analysts?
The average 12-month price target for Pro Medicus Ltd is 202,47 AUD, with a high estimate of 250 AUD and a low estimate of 60 AUD. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +11,57% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.